Finance

Beta
Lists
AZN:LON
AstraZeneca PLC (US)
GBX 13,794.00
+0.42%
(+58.00) 1D
May 29, 4:26:54 PM GMT+1  ·   GBX
All symbols
SymbolPriceChange% Change
Generating top insights for AZN...
Open
GBX 13,812.00
High
GBX 13,916.00
Low
GBX 13,688.00
Mkt. cap
213.72B
Avg. vol.
1.98M
Volume
715.59K
Dividend
1.71%
Quarterly dividend
GBX 59.05
Ex-dividend date
Feb 19, 2026
P/E ratio
27.87
52-wk high
GBX 15,732.00
52-wk low
GBX 10,103.00
EPS
GBX 4.95
Shares outstanding
1.55B
No. of employees
96K
Open
GBX 13,812.00
High
GBX 13,916.00
Low
GBX 13,688.00
Mkt. cap
213.72B
Avg. vol.
1.98M
Volume
715.59K
Dividend
1.71%
Quarterly dividend
GBX 59.05
Ex-dividend date
Feb 19, 2026
P/E ratio
27.87
52-wk high
GBX 15,732.00
52-wk low
GBX 10,103.00
EPS
GBX 4.95
Shares outstanding
1.55B
No. of employees
96K
News stories
From sources across the web
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
14.46B
15.19B
15.50B
15.29B
Cost of goods sold
2.55B
2.79B
3.17B
2.67B
Cost of revenue
2.55B
2.79B
3.17B
2.67B
Research and development expenses
3.51B
3.63B
3.62B
3.47B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.98B
5.20B
5.32B
5.03B
Operating expense
8.42B
8.74B
8.99B
8.34B
Total operating expenses
10.97B
11.53B
12.16B
11.02B
Operating income
3.49B
3.66B
3.35B
4.27B
Other non operating income
-
-
-247.00M
-
EBT including unusual items
3.13B
3.24B
2.63B
3.91B
EBT excluding unusual items
3.11B
3.32B
3.05B
3.94B
Income tax expense
679.00M
709.00M
300.00M
833.00M
Effective tax rate
21.71%
21.86%
11.41%
21.28%
Other operating expenses
-72.00M
-89.00M
53.00M
-155.00M
Net income
2.45B
2.53B
2.33B
3.08B
Net profit margin
16.95%
16.67%
15.00%
20.15%
Earnings per share
2.17
2.38
2.12
1.29
Interest and investment income
65.00M
85.00M
135.00M
73.00M
Interest expense
-436.00M
-434.00M
-155.00M
-393.00M
Net interest expenses
-371.00M
-349.00M
-20.00M
-320.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.88B
5.21B
4.11B
5.64B
Gain or loss from assets sale
-21.00M
-31.00M
-37.00M
-34.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer